DE69333950D1 - Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden - Google Patents
Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor LigandenInfo
- Publication number
- DE69333950D1 DE69333950D1 DE69333950T DE69333950T DE69333950D1 DE 69333950 D1 DE69333950 D1 DE 69333950D1 DE 69333950 T DE69333950 T DE 69333950T DE 69333950 T DE69333950 T DE 69333950T DE 69333950 D1 DE69333950 D1 DE 69333950D1
- Authority
- DE
- Germany
- Prior art keywords
- receptors
- oligomerization
- activation
- receptor ligands
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US885971 | 1986-07-15 | ||
US07/884,811 US5316921A (en) | 1992-05-18 | 1992-05-18 | Single-chain hepatocyte growth factor variants |
US07/885,971 US5328837A (en) | 1992-05-18 | 1992-05-18 | Hepatocyte growth factor protease domain variants |
US884811 | 1992-05-18 | ||
US95057292A | 1992-09-22 | 1992-09-22 | |
US950572 | 1992-09-22 | ||
PCT/US1993/004717 WO1993023550A2 (en) | 1992-05-18 | 1993-05-17 | Activation of oligomerizing receptors by using fused receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69333950D1 true DE69333950D1 (de) | 2006-02-02 |
DE69333950T2 DE69333950T2 (de) | 2006-08-17 |
Family
ID=27420516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333950T Expired - Lifetime DE69333950T2 (de) | 1992-05-18 | 1993-05-17 | Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden |
Country Status (9)
Country | Link |
---|---|
US (1) | US5770704A (de) |
EP (1) | EP0642585B1 (de) |
JP (1) | JPH07508178A (de) |
AT (1) | ATE314479T1 (de) |
CA (1) | CA2117893A1 (de) |
DE (1) | DE69333950T2 (de) |
DK (1) | DK0642585T3 (de) |
ES (1) | ES2257734T3 (de) |
WO (1) | WO1993023550A2 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2715937A1 (fr) * | 1994-02-04 | 1995-08-11 | Bio Merieux | Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. |
US6566098B1 (en) * | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
FR2689520B1 (fr) * | 1992-04-03 | 1996-07-19 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques. |
FR2689521B1 (fr) * | 1992-04-03 | 1996-07-19 | Bio Merieux | Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture. |
JP3824633B2 (ja) * | 1993-02-12 | 2006-09-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ | 標的遺伝子の調節的転写および他の生物学的結果 |
US6891021B2 (en) | 1993-02-12 | 2005-05-10 | Board Of Trustees Of The Leland Stanford Junior University | Regulated apoptosis |
US5830462A (en) * | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5834266A (en) * | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
US5869337A (en) * | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
WO1995021256A1 (fr) | 1994-02-04 | 1995-08-10 | Bio Merieux | Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications |
FR2716198B1 (fr) * | 1994-02-15 | 1996-04-19 | Bio Merieux | Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification. |
WO1995026985A1 (en) * | 1994-04-05 | 1995-10-12 | Board Of Regents, The University Of Texas System | Modified receptors that continuously signal |
WO1996012796A1 (en) * | 1994-10-25 | 1996-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Conditional transformation of genetically engineered cells |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
EP0739984A1 (de) * | 1995-04-26 | 1996-10-30 | San Tumorforschungs-Gmbh | Bivalente Polypeptiden die mindestens zwei Bereichen enthalten |
US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
AU5433701A (en) * | 1995-06-07 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Agonist peptide dimers |
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
FR2737500B1 (fr) | 1995-08-03 | 1997-08-29 | Bio Merieux | Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques |
US6500934B1 (en) * | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
ATE440141T1 (de) | 1996-11-26 | 2009-09-15 | Bio Merieux | Virales material und mit multipler sklerose assoziierte nukleotidfragmente mit diagnostischen,prophylaktischen und therapeutischen verwendungen |
ITMI980179A1 (it) * | 1998-01-30 | 1999-07-30 | Dompe Spa | Proteine ricombinanti derivate da hgf e msp |
ITMI980180A1 (it) * | 1998-01-30 | 1999-07-30 | Dompe Spa | Proteine ricombinanti derivate da hgf e msp |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
DE60134234D1 (de) * | 2000-08-08 | 2008-07-10 | Mgvs Ltd | Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese |
US8389687B2 (en) * | 2000-10-23 | 2013-03-05 | Shanbrom Technologies, Llc | Polyvinylpyrrolidone cryoprecipitate extraction of clotting factors |
US7411006B2 (en) * | 2000-10-23 | 2008-08-12 | Shanbrom Technologies, Llc | Enhanced production of blood clotting factors and fibrin fabric |
US7297716B2 (en) | 2000-10-23 | 2007-11-20 | Shanbrom Technologies, Llc | Enhanced production of blood components, blood cells and plasma without freezing |
SE0004782D0 (sv) * | 2000-12-22 | 2000-12-22 | Schmidt Ann Christin Koch | Blockeringsmedel |
DK1450786T3 (da) * | 2002-06-29 | 2006-04-18 | Aquanova Ger Solubilisate Tech | Isoflavonkoncentrater samt fremgangsmåde til fremstilling deraf |
US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US8227411B2 (en) * | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
WO2005014649A2 (en) * | 2003-08-08 | 2005-02-17 | Pharmacia Corporation | Method for the preparation of molecules having antibody activity |
US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US7671012B2 (en) | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
US7528105B1 (en) | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
ATE482228T1 (de) | 2004-02-20 | 2010-10-15 | Biosurface Eng Tech Inc | Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2) |
PL1773885T3 (pl) | 2004-08-05 | 2010-09-30 | Genentech Inc | Humanizowani antagoniści anty c-met |
SG161281A1 (en) | 2005-04-15 | 2010-05-27 | Genentech Inc | Hgf beta chain variants |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
EP2046350A4 (de) | 2006-06-22 | 2011-09-14 | Biosurface Eng Tech Inc | Zusammensetzungen und verfahren zur freisetzung eines bmp-2-amplifikators/coaktivators für verstärkte osteogenese |
EP2346526A2 (de) | 2008-09-22 | 2011-07-27 | Massachusetts Institute of Technology | Zusammensetzungen und verfahren zur verwendung von liganden-dimeren |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
EP2555788B1 (de) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | Neuregulin dimer für einen erbb/her rezeptor für die verwendung in reduzierung der kardiotoxizität |
AR086823A1 (es) | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
ES2887299T3 (es) | 2014-04-03 | 2021-12-22 | Igm Biosciences Inc | Cadena J modificada |
EP3750918A1 (de) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumornekrosefaktor-superfamilienrezeptorbindende moleküle und verwendungen davon |
US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
US10618978B2 (en) | 2015-09-30 | 2020-04-14 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8300693L (sv) * | 1983-02-09 | 1984-08-10 | Sven Lofdahl | Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4931548A (en) * | 1987-01-30 | 1990-06-05 | Techne Corporation | Heterodimer form of transforming growth factor-beta |
DE3834079A1 (de) * | 1988-10-06 | 1990-04-12 | Biotechnolog Forschung Gmbh | Wachstumstimulierendes pdgf-bb und dessen verwendung sowie ein verfahren zu seiner herstellung und der des monomeren |
EP0397834B1 (de) * | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
EP0429586B1 (de) * | 1989-06-09 | 1995-08-02 | Gropep Pty. Ltd. | Wachstumshormonfusionsproteine |
US5108910A (en) * | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
JP3789928B2 (ja) * | 1989-10-12 | 2006-06-28 | オハイオ ユニバーシティ | 成長ホルモンアンタゴニスト |
US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
-
1993
- 1993-05-17 AT AT93911350T patent/ATE314479T1/de active
- 1993-05-17 JP JP6503819A patent/JPH07508178A/ja active Pending
- 1993-05-17 EP EP93911350A patent/EP0642585B1/de not_active Expired - Lifetime
- 1993-05-17 ES ES93911350T patent/ES2257734T3/es not_active Expired - Lifetime
- 1993-05-17 DK DK93911350T patent/DK0642585T3/da active
- 1993-05-17 DE DE69333950T patent/DE69333950T2/de not_active Expired - Lifetime
- 1993-05-17 CA CA002117893A patent/CA2117893A1/en not_active Abandoned
- 1993-05-17 WO PCT/US1993/004717 patent/WO1993023550A2/en active IP Right Grant
-
1997
- 1997-01-31 US US08/792,078 patent/US5770704A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0642585B1 (de) | 2005-12-28 |
EP0642585A1 (de) | 1995-03-15 |
DK0642585T3 (da) | 2006-05-15 |
ES2257734T3 (es) | 2006-08-01 |
ATE314479T1 (de) | 2006-01-15 |
US5770704A (en) | 1998-06-23 |
WO1993023550A2 (en) | 1993-11-25 |
JPH07508178A (ja) | 1995-09-14 |
WO1993023550A3 (en) | 1994-03-03 |
DE69333950T2 (de) | 2006-08-17 |
CA2117893A1 (en) | 1993-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333950D1 (de) | Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden | |
ATE169675T1 (de) | Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor | |
MX9604316A (es) | Anticuerpos agonistas de la proteina tirosina cinasa. | |
DK0760857T5 (da) | Receptor for onkostatin M | |
DK0584082T3 (da) | Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider | |
NO960767L (no) | Protocadherinproteiner og deres anvendelse | |
DK0914325T3 (da) | Modulatorer af funktionen af FAS receptorer og andre proteiner | |
ATE247667T1 (de) | Gdnf-rezeptor und dessen verwendung | |
DE69839340D1 (de) | Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN | |
GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
DK1283217T3 (da) | Antistoffer mod IL-8-receptoren og deres terapeutiske anvendelser | |
DE69026561D1 (de) | Brenner zur Verbrennung von flüssigem Brennstoff | |
WO2002068615A3 (en) | Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives | |
DK94585D0 (da) | Fiberblanding til forstaerkning af materialer, isaer til forstaerkning af hydrauliske bindemidler, blandingens anvendelse og formdele under anvendelse af blandingen | |
DE59105370D1 (de) | Verfahren zum Imprägnieren von Feststoffen mit flüssigen Bindemitteln und dessen Anwendung. | |
ATE432080T1 (de) | Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation | |
Schlessinger | Signal transduction by EGF-receptor and ist mutants | |
NO2002015I1 (no) | Human tumornekrosefaktorreseptor p 75 Fc fusjonsprotein | |
ATE57248T1 (de) | Brenner zur regenerierung von partikelfiltern. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |